Teva Pharmaceutical Acquires U.S. Commercialization Rights for Samsung Bioepis Biosimilars
Teva Pharmaceutical (TEVA) has entered into a strategic agreement with South Korean drugmaker Samsung Bioepis to acquire the U.S. commercialization rights for two biosimilar products. This partnership allows the Israeli-based pharmaceutical company to expand its portfolio of biologics within the United States market. The deal strengthens Teva's position in the competitive biosimilars landscape, leveraging its existing distribution infrastructure to bring Samsung Bioepis's specialized treatments to American patients. The agreement is expected to bolster Teva's long-term revenue streams through high-value biologic alternatives.
Tickers: $TEVA
Topics: Biosimilars Commercialization Rights Pharmaceutical Agreements